Stoke Therapeutics, Inc. STOK
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a CNS/neurology/psychiatry drug developer. Its lead program, zorevunersen (STK-001), is in Phase 3 for Dravet syndrome. Its next catalyst on record is zorevunersen: Pre-NDA meeting with FDA (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: zorevunersen — Pre-NDA meeting with FDA (H2 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| zorevunersen (STK-001) EMPEROR | Dravet syndrome | RNA (siRNA/ASO/mRNA) | Phase 3 |
| STK-002 (OSPREY) | Autosomal dominant optic atrophy (ADOA) | RNA (siRNA/ASO/mRNA) | Phase 1 |
| SYNGAP1 program (co-developed with Acadia) | SYNGAP1-related neurodevelopmental disorder | RNA (siRNA/ASO/mRNA) | Pre-clinical |
Recent results and decisions
- Jun 30, 2026completed enrollment Phase 3 EMPEROR completed enrollment of 162 patients in the U.S., UK and Japan (about 50 through Week 28); no discontinuations; a ~30-patient European cohort still enrolling.
The Company today announced the completion of enrollment of 162 patients into the Phase 3 EMPEROR study of zorevunersen.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.